Essentials
• Emerging evidence shows that patients with liver disease are not protected from thrombotic events.
• We assessed the risk of venous thromboembolism (VTE) in patients with liver disease.
• The presence of VTE resulted in an increase in mortality for patients with liver disease.
• Hospitalized patients with moderate-severe liver disease had low risk of VTE during admission.
Summary. Background and Aims:
Patients with liver disease were traditionally believed to be protected against development of blood clots, but some studies have shown a potential increased risk of venous thrombotic complications. We assessed the risk of venous thromboembolism (VTE) in patients with liver disease. Methods: Data in discharge reports of patients with liver disease and control patients without liver disease were analyzed from the national inpatient sample. Incidence of VTE was compared in patients with mild, moderate-severe or no liver disease, and the impact on in-hospital mortality and length of stay was calculated. Results: The overall incidence of VTE for patients with no liver disease, mild liver disease and moderate-severe liver disease was 2.7, 2.4 and 0.9 per 100 patient discharges, respectively. In the presence of VTE, in-hospital mortality was 10.8%, 5.8%, and 21.7% for the no liver disease, mild disease and moderate-severe liver disease, respectively. The presence of VTE resulted in an increase in mortality for patients with no liver disease (OR, 1.16; 95% CI, 1.14-1.18) and moderate-severe liver disease (OR, 1.63; CI 95%, 1.42-
Introduction
Chronic liver diseases are characterized by decreased levels of most procoagulant factors, reflected in an increased prothrombin time and thrombocytopenia, leading to the assumption that they are a prototype of an acquired bleeding disorder. However, emerging evidence from recent studies shows that the risk of venous thromboembolism (VTE) may be increased in patients with liver disease [1] . Decreased levels of procoagulant proteins are accompanied by increased levels of factor VIII and decreased levels of protein C, both of which contribute to the presence of hypercoagulability of plasma from patients with liver diseases. Thrombotic complications such as portal vein thrombosis and VTE, and bleeding complications such as gastroesophageal bleeding, are recognized complications of cirrhosis [2] . The pro-hemorrhagic and prothrombotic alterations of these patients correlate principally with the severity of liver disease [3] .
Emerging evidence from recent studies shows that individuals with liver disease are not protected from thrombotic events [1] . Epidemiological studies have shown that the risk of VTE may increase in patients with liver disease by approximately 1.7 to 2-fold with respect to controls [1, 4, 5] . The incidence of VTE was higher in cirrhotic patients than in controls in general in a tertiary care hospital [6] , but lower than in patients with heart failure, chronic kidney disease or cancer. On the other hand, one retrospective case-control study in hospitalized cirrhotic patients found that VTE occurred at a rate lower than that reported in general medical patients [3] . Development of VTE is associated with increased length of hospital stay [7] , hospitalization cost [8] and mortality [7] .
The present study aims to compare the risk of VTE among patients with liver disease within a hospital setting and patients without liver disease, while accounting for hospitalization status, which is an important predictor of VTE risk. We have conducted a nationwide and population-based study. We further sought to characterize the impact of VTE on in-hospital mortality and length of stay among the hospitalized liver disease patients.
Material and methods
We identified every patient discharged from Internal Medicine Departments of Spanish Public Health Service hospitals between 1 January 2005 and 31 December 2014. Hospital discharge data were obtained from the Basic Minimum Data Set (BMDS). This BMDS registry is compulsory for every patient admitted to a Spanish National Health Service hospital, a system that cares for more than 90% of the country's population. All centers submit this information to the Spanish Health Ministry. BMDS contains sociodemographic and clinical data for each documented hospital stay, including: sex and age; primary and secondary diagnoses (according to the International Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9-CM] code); primary and secondary procedures; admission and discharge status (discharged home, death, post-acute facility, other hospital or voluntary discharge); length of stay; and hospital characteristics (less than 200 beds; 200-500 beds; 500-1000 beds; more than 1000 beds). For every patient, a diagnosis-related group (DRG) was identified. DRGs are a way of classifying patient hospitalizations by diagnosis and procedure on the assumption that similar costs are expended on patients by using similar resources. Each DRG has a relative weight that reflects the intensity of resources consumed. Patients were considered surgical if they had a procedure performed that required the use of an operating room. Because the patient data that are generally available do not indicate precisely whether a patient was taken to the operating room, surgical patients were identified based on the surgical procedure performed.
Liver disease
Our primary analysis included three groups of patients: liver disease with two subgroups (mild liver disease or moderatesevere liver disease) and controls. Cases were selected if they were discharged with the diagnosis of liver disease: mild liver disease was defined as ICD-9-CM 571.4-571.49 (chronic hepatitis), 571.2 (alcoholic cirrhosis), 571.5 (cirrhosis without mention of alcohol) or 571.6 (bleary cirrhosis); moderatesevere liver disease was defined as having an ICD code within the primary or secondary diagnosis of 572.2-572.8 (hepatic coma, portal hypertension or other sequelae of chronic liver disease) or variceal bleeding (456.0-456.21). The controls were defined as patients without any codes for liver disease, cirrhosis or complications of liver disease.
Our primary population of interest was patients who had concomitant diagnosis codes for both hepatopathy and VTE: ICD-9-MC pulmonary embolism diagnosis codes, 415 The Charlson Co-morbidity Index (CCI) [9] was computed for each patient. This index reflects the number and importance of co-morbid diseases, relies on ICD categories, and was used to adequately adjust for the severity of illnesses. The index, which has been adapted for use with administrative databases, values the presence of 19 medical conditions, with a scale of 1-6 and a total grade between 0 and 37. An index higher than 2 is related to a mortality rate greater than 50% per year.
Complications associated with hepatopathy were also analyzed using appropriate ICD-9-MC codes: portal vein thrombosis (ICD-9-CM: 452), hepatic encephalopathy (ICD-9-CM: 572.2), variceal bleeding (ICD-9-CM: 456.0), ascites (ICD-9-CM: 789.5X) and coagulopathy (286.6) [1, 10] Outcome variables
The primary outcomes were the overall incidence of VTE coded as concomitant diagnosis in patients with liver disease, in-hospital mortality and length of stay. We conducted subgroup analyses to determine whether there were differences in VTE-associated in-hospital mortality and length of stay between those with a primary diagnosis and those with a secondary diagnosis of liver disease.
Statistical analysis
A descriptive analysis of these patients was carried out and the demographic variables among the patients with or without liver disease and with and without VTE were compared. We used the chi-squared test for categorical variables with the Yates correction, the Fisher's exact test for dichotomous variables when the expected value of a cell was less than 5, and Student 0 s t-test or ANOVA for quantitative variables. All the univariate analyses were carried out after adjusting for age and sex. The odds ratios (ORs) and 95% confidence intervals (CIs) were estimated from the regression coefficients. Multiple logistic regression analyses were performed to determine the independent association of liver disease with likelihood of developing VTE, with adjusting for age, sex, Charlson comorbidity and calendar year. We also used multiple logistic and linear regression to determine the association of VTE with in-hospital mortality and length of stay, respectively, while adjusting for age, sex and comorbidity, in patients with liver disease. The threshold for statistical significance was considered to be P < 0.05.
All statistical analyses were carried out with the use of SPSS Software version 16 (SPSS Inc., Chicago, Illinois, USA).
Results
We analyzed 5 942 763 cases that were admitted to internal medicine wards in Spain during the study period. A total of 324 076 patients had a diagnosis of liver disease (5.5%): 188 244 mild liver disease and 135 823 moderatesevere liver disease. Table 1 shows the demographic characteristics for three groups of patients. Patients with liver disease were older than the comparison group without liver disease (72.9 vs. 64.5 vs. 64.8 years, respectively, P < 0.0001). There was a male predominance among patients with liver disease (69.1% vs. 51.4%; OR, 1.56; 95% CI, 1.55-1.57).
Risk of thromboembolism
A total of 157 654 patients had a diagnosis of VTE (2.7%). During admission, the overall incidence of VTE for patients with no liver disease, mild liver disease and moderate-severe liver disease was 2.7, 2.4 and 0.9 per 100 patient discharges, respectively, and was statistically different among all groups (P < 0.001). Characteristics of hospitalized patients with liver disease, with and without VTE, are shown in Table 2 .
Combining all liver disease patients, the overall adjusted odds ratio for VTE was 0.64 (95% CI, 0.64-0.66). Multivariate analysis was conducted to determine the adjusted relationship between liver disease and VTE ( Table 3 ). The adjusted odds ratio for having VTE among patients was 1.13 (95% CI, 1.09-1.16) for mild liver disease and 0.39 (95% CI, 0.37-0.49) for moderatesevere liver disease compared with the absence of liver disease. 
Mortality and VTE
Crude mortality rates in the absence of VTE for patients with no liver disease, mild liver disease and moderate-severe liver disease were 10%, 5.8% and 13.9%, respectively. In the presence of VTE, in-hospital mortality was 10.8%, 5.8% and 21.7% for no liver disease, mild liver disease and moderate-severe liver disease, respectively. The presence of VTE resulted in an increase in mortality for patients with no liver disease after adjustment for age and sex (OR, 1.16; 95% CI, 1.14-1.18), and also in patients with moderate-severe liver disease (OR, 1.63; 95% CI, 1.42-1.88). Table 4 presents the multivariate analysis of predictors of inhospital mortality in patients with moderate-severe liver disease.
Length of stay and VTE
The mean length of stay (LOS) for patients without hepatopathy and with and without VTE was 11.1 (standard deviation [SD] 12.3) and 9.25 (10.8) days. With mild liver disease with and without VTE it was 11.3 (SD 10.3) and 10.1 (SD 10.5) days. For moderate-severe liver disease LOS was 13.9 (SD 13.6) and 10.7 (11.6) days (P < 0.001 for all the comparisons).
Discussion
Our population study using the nationwide in-patient database (BMDS) suggests that VTE will occur in less than 2% of patients with liver diseases during their hospitalizations, and the risk of VTE is decreased by the presence of moderate-severe liver disease. But the development of VTE in these patients is associated with increased length of hospital stay and worse patient outcomes.
Previous population-based studies have reported conflicting results. Studies from the USA [6] demonstrated reduced risk of VTE, but studies from Britain [11] and Denmark [12] found that the risk of VTE is increased in patients with liver disease. The total incidence of VTE varies from 0.33% to 6.32% in several studies. In a systematic review and meta-analysis, about 1% (95% CI, 0.7-1.3%) [13] of patients with liver diseases develop or are diagnosed with VTE during their hospitalizations.
In our series, VTE is associated with increased mortality in patients with moderate-severe liver disease, with an in-hospital mortality for patients with VTE higher than 21.6%. However, the mortality is not increased in patients with mild liver disease and VTE.
Despite the coagulopathy identified with cirrhosis in many patients [3, 4, 5] , VTE associated with hospitalizations in patients with mild hepatopathy still occurs at a significant level and merits targeted interventions to reduce its occurrence. High-risk patients, such as older patients and those with comorbidities or other traditional risk factors for VTE such as immobility, should receive appropriate measures to prevent VTE. However, our findings do not support the theory that VTE events among hospitalized moderate-severe hepatic disease patients are more common than among hospitalized controls.
This study has several limitations that are related to administrative databases. Because laboratory data were not captured in this database, we are unable to measure liver-specific disease severity scales. An additional limitation is that some diagnoses could have been omitted or incorrect. The use of ICD-9-CM codes for identification of cirrhosis has been validated in other similar administrative datasets and has demonstrated very good negative and positive predictive values [14] . Inaccuracies in ICD-9 coding are expected to be non-differential with respect to VTE, and this type of misclassification tends to result in conservative estimates of effect size [3] . We have demonstrated a good correlation between ICD-9-MC coding and diagnosis of VTE [15] . We could not determine the number of hospitalizations per patient because of limitations of the database. Related to the limitations of the database, the adjustment for repeated admissions for complications of liver disease is not possible. On the other hand, the main strength of this database is its large sample size, which facilitates multivariate adjustment.
In conclusion, patients with moderate-severe liver disease have a lower risk of VTE than those without liver disease, but development of thrombosis during admission increases the risk of in-hospital mortality and length of stay. Further prospective studies could help to explore the role of VTE prophylaxis in these patients. 
